No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANEB Anebulo Pharmaceuticals
- 3.000
- +0.040+1.35%
Close Apr 17 16:00 ET
77.80MMarket Cap-7316P/E (TTM)
3.000High2.780Low992Volume2.840Open2.960Pre Close2.83KTurnover0.03%Turnover RatioLossP/E (Static)25.93MShares4.05052wk High12.00P/B11.71MFloat Cap1.62052wk Low--Dividend TTM3.90MShs Float9.330Historical High--Div YieldTTM7.43%Amplitude1.620Historical Low2.852Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What's the Latest?
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,The company's primary focus
Express News | Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
Express News | Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Comments
Watching for answer
$Anebulo Pharmaceuticals(ANEB.US$ Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof
1
LIKE!
$Anebulo Pharmaceuticals(ANEB.US$ Anebulo Receives Positive Feedback From FDA On Path To Advance Phase 3 Clinical Development Of ANEB-001 And Completes Dosing Of Phase 2 Extension.
3
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg